Home > Insider Trading > Filing (0001209191-19-010352)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1131324	Genomic Health Inc	GHDX	Services-Medical Laboratories (8071)	770552594

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1337798	Bradley G Cole	301 Penobscot Drive Redwood City CA 94063	Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-02-12	5,000	$17.18	53,067	No	4	M	Indirect	Held by the Cole Family Trust
Common Stock	Disposition	2019-02-12	5,000	$80.35	48,067	No	4	S	Indirect	Held by the Cole Family Trust
Common Stock	Acquisiton	2019-02-12	10,000	$22.98	58,067	No	4	M	Indirect	Held by the Cole Family Trust
Common Stock	Disposition	2019-02-12	5,935	$80.89	52,132	No	4	S	Indirect	Held by the Cole Family Trust
Common Stock	Disposition	2019-02-12	4,065	$81.48	48,067	No	4	S	Indirect	Held by the Cole Family Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	Held by the Cole Family Trust
No	4	S	Indirect	Held by the Cole Family Trust
No	4	M	Indirect	Held by the Cole Family Trust
No	4	S	Indirect	Held by the Cole Family Trust
No	4	S	Indirect	Held by the Cole Family Trust

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Disposition	2019-02-12	5,000	$0.00	5,000	$17.18
Common Stock	Employee Stock Option (right to buy)	Disposition	2019-02-12	10,000	$0.00	10,000	$22.98

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
26,471		2020-02-18	No	4	M	Direct
26,424		2021-01-27	No	4	M	Direct

Footnotes

Includes an aggregate of 20,554 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 4, 2018.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Represents weighted average sale price. Actual sale prices ranged from $80.03 to $80.78.
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 23 2018.
Represents weighted average sale price. Actual sale prices ranged from $80.41 to $81.40.
Represents weighted average sale price. Actual sale prices ranged from $81.42 to $81.73.
The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter.
The option became exercisable as to 25% of the shares on January 27, 2012, and became exercisable as to 1/48th of the shares each full month thereafter.